Journal of Clinical Oncology
Articles in this Issue
The nodal nexus: Assessing the lymph node dynamics and outcomes in node-positive carcinoma of the penis.
e17030 Background: Although early-stage, organ-confined disease has favorable outcomes, lymph node metastasis is the stron...
Progestin-only implant and breast cancer risk in adolescents and premenopausal women: A systematic review and meta-analysis.
10594 Background: Progestin-only long-acting reversible contraception via subdermal etonogestrel implants (Implanon/Nexpla...
National practice patterns of adjuvant breast hypofractionated radiation therapy completion in early-stage breast cancer.
e13500 Background: The seminal nationwide examination of treatment completion between standard fractionation radia...
Heterogeneity of stereotactic radiosurgery quality across the community.
e14049 Background: Stereotactic radiosurgery (SRS) is a ubiquitous technique for the treatment of brain metastases that de...
Th1/Th2 immune polarization and cancer of unknown primary (CUP) risk in autoimmune disease: A global healthcare cohort study.
e14550 Background: Cancer of unknown primary (CUP) represents 2–5% of global malignancies and remains among the top 10 can...
Immune context as a modulator of MSI-high and TMB-high as predictors of immune checkpoint inhibitor response in breast cancer.
e17638 Background: Microsatellite instability–high (MSI-H) and tumor mutational burden–high (TMB-High) are tissue-agnostic...
Predictive markers of response and toxicity to tarlatamab in patients with extensive stage small cell lung cancer (ES-SCLC): A multi-institutional real-world analysis.
8097 Background: Tarlatamab (tarla) is a novel immunotherapeutic agent for the treatment of relapsed ES-SCLC associated wi...
Leveraging single-cell trajectory analysis and machine learning to build a robust prognostic classifier for triple-negative breast cancer to pinpoint CCDC171 as a master regulator.
1136 Background: Triple-negative breast cancer (TNBC) is limited by high heterogeneity and a lack of robust biomarkers for...
Impact of <i>KRAS</i> co-mutations on the efficacy of durvalumab in patients with locally advanced non–small cell lung cancer (LA-NSCLC) treated with concurrent chemoradiotherapy (ChRT).
8550 Background: Durvalumab improves survival after platinum-based ChRT in LA-NSCLC. Although immunotherapy is effective i...
Effects of baseline neurological disorders on composite gastrointestinal toxicity risk in cancers of the lip, oral cavity, and pharynx, and in breast cancer through the gut-brain axis: A propensity-matched cohort study.
e18127 Background: Neurological disorders (NDs) such as depression and anxiety may influence the gut-brain axis, potential...
Association of SPOP mutation with survival outcomes following <sup>177</sup> Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC).
e17055 Background: 177 Lu-PSMA-617 ( 177 Lu) radioligand thera...
Exploring the genotoxic and tumorigenic potential of artificial food dyes and implications for colorectal cancer risk in socioeconomically disadvantaged communities.
e22580 Background: The artificial food dyes Blue No. 1, Blue No. 2, and Red 40 are common in processed foods and have been...
First-in-human phase I/II study of a highly selective FGFR2 inhibitor 3HP-2827 in patients with advanced solid tumors harboring <i>FGFR2</i> alterations.
3114 Background: Molecular profiling of cholangiocarcinoma (CCA) is highly recommended to guide access to targeted therapi...
Artificial intelligence (AI) foundation model as a predictor of efficacy of next-generation checkpoint inhibition with botensilimab (BOT) + balstilimab (BAL) in solid tumors using pretreatment H&E images.
2535 Background: Predicting immunotherapy response is challenging in treatment-refractory/resistant (R/R) tumors where het...
Everolimus and aromatase inhibitors for advanced and recurrent low-grade serous ovarian carcinoma.
5569 Background: Treatment options for advanced and recurrent low grade serous ovarian carcinoma (LGSOC) are limited. Muta...
Longitudinal plasma and CSF ctDNA profiling as used to define therapeutic landmarks and compartmentalized clonal evolution in rhabdomyosarcoma.
11517 Background: Current risk stratification in rhabdomyosarcoma (RMS) relies on static pretreatment variables, which fai...
Impact of advanced practice provider–led new consults in community oncology: Expanding access and volume in benign hematology.
1531 Background: Community oncology practices face rising patient volumes and workforce shortages, leading to delays in ac...
Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS <sup>G12C</sup> mutant solid tumors from a phase Ib/II study: 2-year follow-up from single-arm of non-small-cell lung cancer (NSCLC).
3113 Background: Studies have shown that combining RAS inhibitors (RASi) with appropriate partners may enhance efficacy. I...
Reduced treatment adherence and cancer mortality in patients with depression.
11040 Background: Depression affects up to 20% of cancer patients and is associated with poorer cancer outcomes. The lack...
Impact of corticosteroid exposure on long-term immune checkpoint inhibitor responses in solid tumors.
12160 Background: Multiple analyses offer conflicting evidence regarding the implications of immune related adverse events...
Updated results from inMMyCAR, the ongoing first-in-human phase 1 study of KLN-1010 in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
7509 Background: KLN-1010 is a modified lentiviral vector generating a novel, fully human anti-BCMA CAR-T cell...
A randomized phase III study of gemcitabine plus cisplatin with S-1 versus gemcitabine plus cisplatin with immune checkpoint inhibitor in unresectable biliary tract cancer.
TPS4252 Background: Gemcitabine plus cisplatin (GC) has been established as the standard first-line treatment for unresect...
Bridging the fertility divide: Disparities across counseling, referral, and utilization of fertility preservation in young breast cancer patients.
e13565 Background: As survival improves for reproductive-age women with breast cancer (BC), fertility preservation (FP) is...
Real-world impact of comprehensive genomic profiling in colon cancer: Evidence from community oncology centers in western India.
e15587 Background: NGS-based mutation profiling is increasingly used to guide oncology treatment. This study compares comp...
Development and clinical utility of an H&E-based tumor origin prediction model.
3021 Background: Tumor of unknown primary origin remains a critical unmet need in oncology, as histologic and anatomic dia...